.
@NIAIDNews
is the official Twitter profile for information from the National Institute of Allergy and Infectious Diseases, part of NIH. You can verify all official NIAID social media channels here:
COVID NEWS: Autopsies of people who died from COVID19 show that the virus spread throughout the body and remained in tissue for months. The study broadened scientists’ perspectives on where SARS-CoV-2 could cause infection and persist, including the brain.
COVID-19 NEWS: A preliminary data analysis from
#NIH
clinical trial shows hospitalized patients w/ advanced
#COVID19
and lung involvement who received the investigational antiviral
#remdesivir
recovered faster than similar patients who received placebo:
NIAID Director, Dr. Anthony Fauci will be rolling up his sleeve tomorrow to get
@moderna_tx
#COVID19
vaccine alongside
@SecAzar
,
@NIHDirector
, and several
@NIHClinicalCntr
frontline workers to build confidence in the vaccine, which is the best hope against this pandemic.
A2:
#Vaccines
are important for people of all ages. The more people in a given population who are vaccinated for a disease, the less likely that disease will spread. This is called “herd immunity,” and it helps protect people who can’t get vaccines.
#HHSVaxChat
NEWS:
@EmoryUniversity
in Atlanta will begin enrolling healthy adult volunteers in a Phase 1 clinical trial of a vaccine designed to prevent
#coronavirus
disease. The trial began in Seattle last week & will enroll a total of 45 people across the 2 sites:
VOLUNTEERS NEEDED: The NIH Vaccine Research Center is looking for volunteers to donate blood for studies on the immune system. Participants will be compensated for their time and convenience. To volunteer, call 1-866-833-5433 (TTY 1-866-411-1010) or email vaccines
@nih
.gov.
#COVID19
NEWS: An
#NIH
-funded study on the incidence of novel
#coronavirus
infection in U.S. children has begun. The study also will examine whether infection rates differ between children who do & do not have
#asthma
or other
#allergic
conditions.
NEWS: New data shows mRNA-1273, an investigational vaccine developed by
#NIAID
and
@moderna_tx
, protects mice from infection with
#SARSCoV2
. The findings are available on the preprint server bioRxiv and are not yet peer-reviewed.
NEWS: NIH has begun a clinical trial to evaluate the safety and efficacy of the investigational antiviral
#remdesivir
in hospitalized adults diagnosed with
#COVID19
.
#COVID19
NEWS:
@NIH
begins study to quantify undetected cases of
#coronavirus
infection. Blood samples from healthy volunteers are needed to inform public health decision making. Read more:
📸:
@NIBIBgov
NEWS: An experimental
#HIVvaccine
regimen elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of
#HIV
strains from around the world. Learn more:
#NIH
#NIAID
NEWS: Dr. Fauci announced today that he will be stepping down in Dec. 2022 from the positions of NIAID Director and Chief of the NIAID Laboratory of Immunoregulation, as well as the position of Chief Medical Advisor to President Joe Biden.
Powerful
#HIV
prevention and treatment tools can help us end the U.S. HIV epidemic. Science has laid the groundwork for this bold new initiative.
#SOTU
The Epstein-Barr virus, the key cause of mononucleosis and linked to some cancers and autoimmune diseases, is the target of a new early-stage NIAID vaccine trial. Read more:
COVID-19 NEWS: A
@NIAIDNews
-supported study has found that most
#COVID19
vaccine-elicited T-cell responses to
#SARSCoV2
recognize all variants of concern in adults up to 7 months after vaccination.
FLU NEWS: A nanoparticle
#flu
#vaccine
that could deliver lasting protection from many flu strains has entered early-stage human trial at
#NIH
. The investigational vaccine, FluMost-v1, was developed by scientists from the
#NIAID
Vaccine Research Center.
NEWS: An engineered antibody derived from llama antibodies may neutralize
#SARSCoV2
, the virus that causes
#COVID19
, report researchers at NIAID,
@TexasScience
&
@ResearchUGent
🦙Further research into these proteins may help scientists find new treatments:
#COVID19
News: A
@NIAIDNews
-funded study published in
@ScienceMagazine
has found that memory T cells are the source of pre-existing reactivity against
#SARSCoV2
, explaining how some people who have never been exposed to the virus have reactivity to it.
COVID19 NEWS: Early results of
#NIAID
-sponsored ph1 trial of experimental
#SARSCOV2
vaccine mRNA-1273: two doses generally well tolerated and prompted a robust immune response in healthy adults.
NEWS:
#Remdesivir
improves time to recovery for people hospitalized with
#COVID19
, according to a peer-reviewed preliminary analysis published today in
@NEJM
. The results are from the
#NIH
randomized, placebo-controlled trial that began on Feb. 21
#HIV
NEWS: Long-acting injectable
#cabotegravir
prevents HIV acquisition among cisgender women,
@NIAIDNews
-sponsored study finds. The long-acting
#PrEP
regimen was safe & more effective than daily oral PrEP among African women.
MONKEYPOX NEWS: In the coming weeks,
#NIAID
plans to initiate clinical trials evaluating the antiviral tecovirimat (TPOXX) for
#monkeypox
and a clinical trial evaluating dose-sparing regimens of JYNNEOS, a vaccine approved to prevent monkeypox. Read more
COVID-19 NEWS: Neutralizing antibody activity against all variants of
#SARS
-CoV-2, including Delta, lasted 6 months in people who got 2 doses of
#COVID19
mRNA
#vaccine
. Findings online now
@ScienceMagazine
COVID-19 NEWS: College students can enroll in a study designed to determine if Moderna’s vaccine can prevent
#SARSCoV2
infection, limit amount of virus in the nose & reduce transmission of SARS-CoV-2 from those vaccinated to their close contacts.
MALARIA NEWS: One dose of a new monoclonal antibody discovered and developed at
@NIAIDNews
safely prevented
#malaria
for up to nine months in people who were exposed to the
#Plasmodium
parasite. The finding was published online yesterday in
@NEJM
.
COVID-19 NEWS: volunteers who received two doses of the
@moderna_tx
#COVID19
vaccine in spring 2020 as part of an
#NIH
-led Phase 1 trial retained high levels of antibodies 6 months after the second dose, according to new data published in
@NEJM
today.
33 participants who received both doses of the Moderna mRNA-1273 vaccine had blood drawn over 6 months after vaccination.
#SARSCoV2
neutralizing activity was maintained in all the patients. A half-life of 202 days was determined for the live-virus neutralization activity.
Universal flu vaccine news:
#NIAID
-funded scientists developed a novel anti-
#flu
antibody derived from llamas that could protect against a variety of
#influenza
A & B viruses
Eczema News:
#NIAID
scientists have found a link between widely used chemicals called diisocyanates and
#eczema
. They’ve also showed that skin bacteria exposed to isocyanate stop producing oils necessary for skin to stay healthy. Read more:
#VACCINE
NEWS: mRNA vaccines may someday shield us from more than
#COVID19
: In an NIAID-supported study published in
@ScienceMagazine
last week, mRNA vaccines protected mice from viruses with pandemic potential.
A new study shows that mRNA vaccines designed to express chimeric spike protein protect aged mice against epidemic, zoonotic, and pandemic SARS-like viruses.
@David_RMartinez
@Baric_Lab
A Phase 3 clinical trial of the investigational mRNA-1273 vaccine for
#COVID19
has begun. The vaccine was co-developed by
@moderna_tx
and
#NIAID
scientists. The trial will enroll 30,000 adult volunteers at nearly 90 sites in the US
Antibody and immune stimulant treatment for
#HIV
delayed viral rebound in half of treated monkeys for over 6 months, NIH-supported scientists announce at
#CROI2018
. The treatment may also target viral reservoir, with implications for HIV remission research
INFLUENZA NEWS: Scientists at NIAID’s
#Vaccine
Research Center report in two new studies that an experimental
#influenza
vaccine, designed to protect against a broad range of flu viruses, performed well in a Phase 1 trial and has advanced to a second trial
FLU NEWS: An mRNA vaccine candidate designed to protect against all known influenza virus subtypes shows promise in preclinical studies, according to a new report by NIAID-supported researchers
@PennMedicine
published in
@ScienceMagazine
.
NIAID's influenza research program is working to develop a universal flu vaccine to provide robust, long-lasting protection against multiple subtypes of flu. A
#UniversalFluVaccine
would eliminate the need to update & administer the seasonal flu vaccine each year.
#NIAM
HIV NEWS: A vaginal ring for
#HIV
prevention has received a positive opinion from
@EMA_News
for use by cisgender women in developing countries!
@NIAIDNews
celebrates this pivotal step toward expanding
#HIVprevention
choices for women.
#WomensHealth
August is National Immunization Awareness Month! This month, we will be sharing information about
#vaccines
that NIAID has helped develop and trials that are ongoing to evaluate potential vaccines.
#ivax2protect
#NIAM2022
COVID-19 NEWS: The disease spread by a novel
#coronavirus
is causing worldwide disruption. How did we get here, and can swift public health actions prevent a
#pandemic
?
#NIAID
scientists offer perspective:
#COVID19
#COVID19
NEWS: A new study demonstrates an association between high blood plasma antigen levels and worse patient outcomes in severe SARS-CoV-2 infections.
Entertainer
@JVN
discussed
#UEqualsU
on
@TODAYshow
, explaining that people living with
#HIV
cannot pass on the virus if they maintain durable viral suppression. Learn more on
#NIAIDNow
:
#COVID19
NEWS:
@NIAIDNews
research published in
@CellCellPress
finds some people experience a late “second wave” of immune responses to
#SARSCoV2
infection that is associated with more severe disease & death.
Today
@NIH
issued the Strategic Plan for
#Herpes
Simplex Virus (HSV) Research, developed by the NIH-wide
#HSV
Working Group and informed by feedback from 100+ research and advocacy community representatives and the public. Learn more:
CORONAVIRUS NEWS: The NIH has awarded $36.3 million to three institutions to develop “pan-coronavirus” vaccines that protect against multiple coronaviruses AND variants.
VIDEO:
@NIAIDNews
Director Anthony S. Fauci says we have the scientific tools right now that—if properly implemented—could stop the
#HIV
epidemic in its tracks. The challenge is to overcome what he calls an “implementation gap.”
#NIAID
#NIH
#Solvable
March 24 is World Tuberculosis (TB) Day. TB is the second leading infectious killer in the world after COVID-19. During the coronavirus pandemic, reduced access to care interrupted TB control, resulting in more deaths.
A key focus of NIAID’s
#influenza
research program is developing a universal
#flu
vaccine---one that could protect against multiple flu subtypes and eliminate the need for an annual seasonal flu vaccine. Read more at
#NIAM2022
A study by
@gardp_amr
&
@innovivastx
found the novel antibiotic zoliflodacin was as safe & effective as standard therapy for uncomplicated urogenital
#gonorrhea
.
#NIAID
supported dev't of zoliflodacin & applauds partners on completing the study. Read more:
NEWS: Dr. Fauci & colleagues note in
@JAMA_current
: a return to normalcy will require widespread adoption of masks & other interventions to prevent
#SARSCoV2
spread (distancing; hand hygiene; testing, isolation & contact tracing; limiting crowds):
#HIV
NEWS: Long-acting injectable form of HIV
#PrEP
outperforms daily pill in
@NIAIDNews
study. Both methods were highly effective at preventing HIV among MSM and TGW,
@HIVptn
scientists report at
#AIDS2020
.
3 different
#HIV
#antibodies
isolated by the
#NIAIDVRC
each protected monkeys from acquiring simian-HIV. The antibodies target the fusion peptide on HIV. Findings support continued development of this concept for an HIV
#vaccine
for people. Read more:
#NIH
COVID-19 NEWS: Today, two Phase 3 trials to test potential therapeutics for
#COVID19
began enrolling participants. The two trials, part of the ACTIV-3 master protocol, will test monoclonal
#antibody
therapeutics in hospitalized participants.
#COVID19
NEWS: Preliminary results of
#NIAID
-sponsored trial examining mRNA COVID-19
#vaccines
containing
#Omicron
variant used as a second boost dose now posted as a pre-print:
On
#WorldAIDSDay
,
@NIH
reflects on both the remarkable progress that has been made against
#HIV
& the considerable challenges that remain. Read a statement from
@NIAIDNews
Director Dr. Fauci &
@NIH_OAR
Director Dr. Goodenow:
#FLU
NEWS:
#NIAID
#ClinicalTrial
of a nanoparticle flu
#vaccine
found it was safe and prompted an immune response. Such vaccines could one day provide long-lasting protection from many flu
#virus
subtypes.
COVID-19 vaccines available in the United States are effective at protecting people from getting seriously ill, being hospitalized, and even dying—especially people who are boosted.
@CDCgov
recommends that everyone 6 months and older get vaccinated against
#COVID19
#NIAM2022
COVID NEWS: NIAID scientists find experimental antiviral for
#COVID19
effective in hamster study. MK-4482, also known as
#molnupiravir
and EIDD-2801, originally developed to treat influenza.
BLOG: January 30th is World Neglected Tropical Diseases (NTD) Day. Learn about how NIAID is helping to
#EndTheNeglect
of NTDs and supporting the global effort to prevent, control, and eliminate these diseases on the
#NIAIDNow
blog:
#WorldNTDday
#BeatNTDs
On
#WorldAIDSDay
35, NIAID remembers the many lives affected by the HIV pandemic and remains committed to collective efforts with research and community partners to end HIV for all.
Read the NIH World AIDS Day statement: